Overview Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors Status: Completed Trial end date: 2012-07-01 Target enrollment: Participant gender: Summary Safety study of ABT-263 in Combination with Paclitaxel in Subjects with Solid Tumors. Phase: Phase 1 Details Lead Sponsor: AbbottAbbVieCollaborator: Genentech, Inc.Treatments: Albumin-Bound PaclitaxelNavitoclaxPaclitaxel